Body Fat Distribution Contributes to Defining the Relationship between Insulin Resistance and Obesity in Human Diseases.

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM
María M Adeva-Andany, Alberto Domínguez-Montero, Lucía Adeva-Contreras, Carlos Fernández-Fernández, Natalia Carneiro-Freire, Manuel González-Lucán
{"title":"Body Fat Distribution Contributes to Defining the Relationship between Insulin Resistance and Obesity in Human Diseases.","authors":"María M Adeva-Andany, Alberto Domínguez-Montero, Lucía Adeva-Contreras, Carlos Fernández-Fernández, Natalia Carneiro-Freire, Manuel González-Lucán","doi":"10.2174/1573399820666230816111624","DOIUrl":null,"url":null,"abstract":"<p><p>The risk for metabolic and cardiovascular complications of obesity is defined by body fat distribution rather than global adiposity. Unlike subcutaneous fat, visceral fat (including hepatic steatosis) reflects insulin resistance and predicts type 2 diabetes and cardiovascular disease. In humans, available evidence indicates that the ability to store triglycerides in the subcutaneous adipose tissue reflects enhanced insulin sensitivity. Prospective studies document an association between larger subcutaneous fat mass at baseline and reduced incidence of impaired glucose tolerance. Case-control studies reveal an association between genetic predisposition to insulin resistance and a lower amount of subcutaneous adipose tissue. Human peroxisome proliferator-activated receptorgamma (PPAR-γ) promotes subcutaneous adipocyte differentiation and subcutaneous fat deposition, improving insulin resistance and reducing visceral fat. Thiazolidinediones reproduce the effects of PPAR-γ activation and therefore increase the amount of subcutaneous fat while enhancing insulin sensitivity and reducing visceral fat. Partial or virtually complete lack of adipose tissue (lipodystrophy) is associated with insulin resistance and its clinical manifestations, including essential hypertension, hypertriglyceridemia, reduced HDL-c, type 2 diabetes, cardiovascular disease, and kidney disease. Patients with Prader Willi syndrome manifest severe subcutaneous obesity without insulin resistance. The impaired ability to accumulate fat in the subcutaneous adipose tissue may be due to deficient triglyceride synthesis, inadequate formation of lipid droplets, or defective adipocyte differentiation. Lean and obese humans develop insulin resistance when the capacity to store fat in the subcutaneous adipose tissue is exhausted and deposition of triglycerides is no longer attainable at that location. Existing adipocytes become large and reflect the presence of insulin resistance.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":null,"pages":null},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573399820666230816111624","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The risk for metabolic and cardiovascular complications of obesity is defined by body fat distribution rather than global adiposity. Unlike subcutaneous fat, visceral fat (including hepatic steatosis) reflects insulin resistance and predicts type 2 diabetes and cardiovascular disease. In humans, available evidence indicates that the ability to store triglycerides in the subcutaneous adipose tissue reflects enhanced insulin sensitivity. Prospective studies document an association between larger subcutaneous fat mass at baseline and reduced incidence of impaired glucose tolerance. Case-control studies reveal an association between genetic predisposition to insulin resistance and a lower amount of subcutaneous adipose tissue. Human peroxisome proliferator-activated receptorgamma (PPAR-γ) promotes subcutaneous adipocyte differentiation and subcutaneous fat deposition, improving insulin resistance and reducing visceral fat. Thiazolidinediones reproduce the effects of PPAR-γ activation and therefore increase the amount of subcutaneous fat while enhancing insulin sensitivity and reducing visceral fat. Partial or virtually complete lack of adipose tissue (lipodystrophy) is associated with insulin resistance and its clinical manifestations, including essential hypertension, hypertriglyceridemia, reduced HDL-c, type 2 diabetes, cardiovascular disease, and kidney disease. Patients with Prader Willi syndrome manifest severe subcutaneous obesity without insulin resistance. The impaired ability to accumulate fat in the subcutaneous adipose tissue may be due to deficient triglyceride synthesis, inadequate formation of lipid droplets, or defective adipocyte differentiation. Lean and obese humans develop insulin resistance when the capacity to store fat in the subcutaneous adipose tissue is exhausted and deposition of triglycerides is no longer attainable at that location. Existing adipocytes become large and reflect the presence of insulin resistance.

体脂分布有助于确定人类疾病中胰岛素抵抗与肥胖之间的关系。
肥胖导致代谢和心血管并发症的风险是由身体脂肪分布而非整体脂肪含量决定的。与皮下脂肪不同,内脏脂肪(包括肝脏脂肪变性)反映了胰岛素抵抗,并可预测 2 型糖尿病和心血管疾病。现有证据表明,在人体皮下脂肪组织中储存甘油三酯的能力反映了胰岛素敏感性的增强。前瞻性研究表明,基线时皮下脂肪量较大与糖耐量受损发生率降低之间存在关联。病例对照研究显示,胰岛素抵抗的遗传易感性与皮下脂肪组织较少之间存在关联。人类过氧化物酶体增殖激活受体γ(PPAR-γ)可促进皮下脂肪细胞分化和皮下脂肪沉积,改善胰岛素抵抗并减少内脏脂肪。噻唑烷二酮类药物再现了 PPAR-γ 激活的效果,因此会增加皮下脂肪量,同时增强胰岛素敏感性并减少内脏脂肪。部分或几乎完全缺乏脂肪组织(脂肪营养不良)与胰岛素抵抗及其临床表现有关,包括原发性高血压、高甘油三酯血症、高密度脂蛋白胆固醇降低、2 型糖尿病、心血管疾病和肾脏疾病。普拉德-威利综合征患者表现为严重的皮下肥胖,但没有胰岛素抵抗。皮下脂肪组织积聚脂肪的能力受损可能是由于甘油三酯合成不足、脂滴形成不足或脂肪细胞分化缺陷所致。当皮下脂肪组织储存脂肪的能力耗尽,甘油三酯无法在该部位沉积时,瘦人和肥胖者就会出现胰岛素抵抗。现有的脂肪细胞体积变大,反映出胰岛素抵抗的存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信